Home > Insider Trading > Filing (0001209191-12-037891)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1012140	Onyx Pharmaceuticals Inc	ONXX	Biological Products, (No Disgnostic Substances) (2836)	943154463

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1225509	M Suzanne Shema	C/O Onyx Pharmaceuticals, Inc. 249 East Grand Ave. South San Francisco CA 94080	Evp, General Counsel & Sec	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2012-07-09	16,747	$32.07	70,386	No	4	M	Direct
Common Stock	Acquisiton	2012-07-09	7,719	$30.28	78,105	No	4	M	Direct
Common Stock	Disposition	2012-07-09	20,201	$67.49	57,904	No	4	S	Direct
Common Stock	Disposition	2012-07-09	4,265	$68.53	53,639	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2012-07-09	16,747	$0.00	16,474	$32.07
Common Stock	Stock Option (Right to Buy)	Disposition	2012-07-09	7,719	$0.00	7,719	$30.28

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
30,526		2019-08-31	No	4	M	Direct
13,781		2020-03-31	No	4	M	Direct

Footnotes

Shares sold pursuant to a 10b5-1 plan.
The shares were sold between $67.07 and $67.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares were sold between $68.02 and $68.62. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Twenty-Five percent of the shares subject to the option become exercisable one year from the date of grant. The remaining shares become exercisable in equal monthly installments over the following 36 months for a total vesting schedule of 48 months.
12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.